

Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis [Corrigendum]

Kameoka Y, Kishi F, Koura M, et al. *Drug Des Devel Ther.* 2019;13:555–568.

The authors have advised that there was an error in the text.

Page 561, beginning at the left-hand bottom of the page, “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: $4.42 (1.36–7.57) \times 10^9$ cells/L vs 3.14

$(1.48–15.7) \times 10^9$ cells/L (Figure S3A). The number of granulocytes decreased: $0.15 (0.05–1.04) \times 10^9$ cells/L vs $0.22 (0.04–0.69) \times 10^9$ cells/L (Figure S3B).” should instead read “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: $2.11 (1.36–2.44) \times 10^9$ cells/L vs $3.14 (1.48–15.7) \times 10^9$ cells/L (Figure S3A). The number of granulocytes decreased: $0.055 (0.03–0.08) \times 10^9$ cells/L vs $0.22 (0.04–0.69) \times 10^9$ cells/L (Figure S3B).”